摘要
人DNA拓扑异构酶Ⅱα(topoisomerase Ⅱα, Topo Ⅱα)是重要的抗肿瘤药物研究靶标之一.前期研究发现对联三苯类化合物对TopoⅡα有抑制作用,并且抑制人乳腺导管癌细胞增殖.本研究通过对联三苯类化合物的骨架跃迁,设计合成了19个6-取代芳基-2-甲氧基喹啉类衍生物3a~3s,包括取代苯基、氮硫杂环和萘环等.体外人三阴乳腺癌MDA-MB-231细胞株生长抑制实验和Topo Ⅱα抑制实验结果表明, 6-(4-羟甲基苯基)-2-甲氧基喹啉(3b)有明显细胞毒性和Topo Ⅱα抑制活性(IC_(50)=9.9μmol·L~(-1)).研究结果为研发新型Topo Ⅱα抑制剂提供了新方向,对肿瘤的预防和治疗具有重要意义.
Human DNA Topoisomerase Ⅱα(Topo Ⅱα) is one of the important therapeutic targets for the treatment of cancers.Our previous study showed that p-terphenyls have inhibitory effects on Topo Ⅱα and inhibit the proliferation of human breast ductal carcinoma cells. In this study, nineteen 6-substituted aryl-2-methoxyquinolines(3a~3s) were designed, synthesized and evaluated for their cytotoxicity against the growth of human triple negative breast cancer MDA-MB-231 cell line and inhibitory activity against Topo Ⅱα. Among these compounds, 6-(4-(hydroxymethyl)phenyl)-2-methoxyquinoline(3b) showed the most potent activity(IC_(50)=9.9 μmol·L~(-1)). These results have important significance for the further study of aryl quinoline TopoⅡα inhibitors.
引文
[1]Wang, J. C. Annu. Rev. Biochem. 1996, 65, 635.
[2]Azarova, A. M.; Lyu, Y. L.; Lin, C. P.; Tsai, Y. C.; Lau, J. Y.; Wang,J. C.; Liu, L. F. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 11014.
[3]Deweese, J. E.; Osheroff, N. Nucleic Acids Res. 2009, 37, 738.
[4]Haffner, M. C.; Aryee, M. J.; Toubaji, A.; Esopi, D. M.; Albadine,R.; Gurel, B.; Isaacs, W. B.; Bova, G. S.; Liu, W.; Xu, J.; Meeker, A.K.; Netto, G.; De Marzo, A. M.; Nelson, W. G.; Yegnasubramanian,S. Nat. Genetics 2010, 42, 668.
[5]Liu,S.S.;Zhao,B.B.;Lu,C.H.;Huang,J.J.;Shen,Y.M.Nat.Prod. Commun. 2012, 7, 1057.
[6]Qiu, J.; Zhao, B.; Shen, Y.; Chen, W.; Ma, Y.; Shen, Y. Eur. J. Med.Chem. 2013, 68, 192.
[7]Ibrahim,M.K.;Taghour,M.S.;Metwaly,A.M.;Belal,A.;Mehany,A. B. M.;Elhendawy,M. A.;Yassin, M. M.; Yassin, A.M.;El-Deeb,N.M.;Hafez,E.E.;Elsohly,M.A.;Eissa,I.H.Eur.J.Med. Chem. 2018, 115, 117.
[8]Kaur, G.; Cholia, R. P.; Joshi, G.; Amrutkar, S. M.; Kalra, S.; Mantha, A. K.; Banerjee, U. C.; Kumar, R.. Pham. Chem. Life Sci. 2018,351, e1800023.
[9]Ruchelman, A. L.; Singh, S. K.; Wu, X.; Ray, A.; Yang, J. M.; Li, T.K.; Liu, A.; Liu, L. F.; LaVoie, E. J. Bioorg. Med. Chem. Lett. 2002,12, 3333.
[10]Lu, C. M.; Chen, Y. L.; Chen, H. L; Chen, C. A.; Lu, P. J.; Yang, C.N.; Tzeng, C. C. Bioorg. Med. Chem. 2010, 18, 1948.
[11]Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Cancer Res 1987, 47, 936.
[12]Huang,Y.;Wang,J.;Li,G.;Zheng,Z.;Su,W.FEMSImmunol.Med. Microbiol. 2001, 31, 163.
[13]Chen, W.; Shen, Y.; Li, Z.; Zhang, M.; Lu, C.; Shen, Y. Eur. J. Med.Chem. 2014, 86, 782.
[14]Shen, Y.; Chen, W.; Zhao, B.; Hao, H.; Li, Z.; Lu, C.; Shen, Y. Biochem. Biophys. Res. Commun. 2014, 453, 302.
[15]Shen, Y.; Chen, W.; Li, Z.; Shen, Y. Med. Chem. 2014, 10, 533.
[16]Barrett,J.;Sutcliffe,J.;Gootz,T.Antimicrob.AgentsChemother.1990, 34, 1.
[17]Marini, J. C.; Levene, S. D.; Crothers, D. M.; Englund, P. T. Proc.Natl. Acad. Sci. 1982, 79, 7664.
[18]Xiao, X.; Cushman, M. J. Am. Chem. Soc. 2005, 127, 9960.
[19]Trott, O.; Olson, A. J. J. Comput. Chem. 2010, 31, 455.
[20]Sanner, M. F. J. Mol.-Graphies Modell. 1999, 17, 57.
[21]Morris,G.M.;Huey,R.;Lindstrom,W.;Sanner,M.F.;Belew,R.K.; Goodsell, D. S.; Olson, A. J. J. Comput. Chem. 2009, 30, 2785.